source
- Teva named stalking horse bidder to acquire BioXcel's neuroscience assets for $57.5 millionBioXcel Therapeutics, a Connecticut biotech focused on neuroscience, filed for Chapter 11 bankruptcy after running out of cash to fund operations through August. In the filing, the company selecte…
- Revolution Medicines' Rasonge receives second-line pancreatic cancer nod, could drive $2.3B sales by 2028Revolution Medicines announced that its RAS inhibitor Rasonge earned a second-line indication for pancreatic ductal adenocarcinoma, marking the first regulatory step in the company's PDAC strategy.…